Rapid transition to home omalizumab treatment for chronic spontaneous urticaria during the COVID-19 pandemic: A patient perspective
Efforts to reduce non-urgent hospital attendances during the COVID-19 pandemic have been the focus of much attention from healthcare professionals worldwide. In Ireland, due to funding constraints omalizumab is only available for hospital-based administration. Fifty-eight patients with chronic spont...
Enregistré dans:
Auteurs principaux: | Catherine King, Fionnuala Cox, Anne Sloan, Patricia McCrea, J.David Edgar, Niall Conlon |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Elsevier
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/55bf881013204d3b9915fc5d9d0dba69 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Exploring Machine Learning Techniques to Predict the Response to Omalizumab in Chronic Spontaneous Urticaria
par: Davide Stefano Sardina, et autres
Publié: (2021) -
Two decades with omalizumab: what we still have to learn
par: Incorvaia C, et autres
Publié: (2018) -
Aetiology of urticaria in children
par: S. N. Buinova, et autres
Publié: (2017) -
Omalizumab for prevention of anaphylactic episodes in a patient with severe mosquito allergy
par: Elisa Meucci, et autres
Publié: (2021) -
Guía clínica chilena de urticaria crónica espontánea
par: Aguilera-Insunza,Raquel, et autres
Publié: (2018)